MLN 3897
Modify Date: 2025-08-30 20:28:45
MLN 3897 structure
|
Common Name | MLN 3897 | ||
|---|---|---|---|---|
| CAS Number | 1010731-97-1 | Molecular Weight | 535.125 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H39ClN2O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MLN 3897MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5; inhibits osteoclastogenesis and OC activity by impairing multinucleation and by down-regulation of c-fos signaling, inhibits osteoclastogenesis and OC activity by impairing multinucleation and by down-regulation of c-Fos signaling; demonstrates potential for the treatment of multiple sclerosis and rheumatoid arthritis. Multiple Sclerosis Phase 1 Discontinued |
| Name | MLN 3897 |
|---|
| Description | MLN 3897 is a potent, specific and orally active antagonist of CCR1 with IC50 of 0.8 nM in competition binding assays, 500-fold selectivity over CCR5; inhibits osteoclastogenesis and OC activity by impairing multinucleation and by down-regulation of c-fos signaling, inhibits osteoclastogenesis and OC activity by impairing multinucleation and by down-regulation of c-Fos signaling; demonstrates potential for the treatment of multiple sclerosis and rheumatoid arthritis. Multiple Sclerosis Phase 1 Discontinued |
|---|---|
| References | References 1. Gilchrist A, et al. Br J Pharmacol. 2014 Nov;171(22):5127-38. 2. Vallet S, et al. Blood. 2007 Nov 15;110(10):3744-52. 3. Lu C, et al. J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. 4. Vergunst CE, et al. Arthritis Rheum. 2009 Dec;60(12):3572-81. View Related Products by Target Chemokine Receptor (CCR and CXCR) Multiple Sclerosis |
| Molecular Formula | C32H39ClN2O3 |
|---|---|
| Molecular Weight | 535.125 |
| InChIKey | NVBMQDQKIKYLDW-WXTRKPKDSA-N |
| SMILES | CC1(C)CN(CCC=C2c3cc(C(=O)O)ccc3OCc3ncccc32)CCC1(O)c1ccc(Cl)cc1 |